잠시만 기다려 주세요. 로딩중입니다.

대장암 항암요법에서의 최근 신경향

New Trend in Chemotherapy for Colorectal Cancer

대한대장항문학회지 2004년 20권 2호 p.118 ~ 123
김영진, 김홍대,
소속 상세정보
김영진 ( Kim Young-Jin ) - 전남대학교 의과대학 외과학교실
김홍대 ( Kim Heung-Dae ) - 성균관대학교 의과대학 강북삼성병원 외과학교실

Abstract


5-Fluorouracil (5-FU) has been the main chemotherapeutic agent for the treatment of colorectal cancer for four decades with modest efficacy. Modulation of 5-FU by leucovorin or continuous infusion improves the response rate, but overall survival duration remains approximately 12 months. Many oral fluoropyrimidines have been studied, including capecitabine, UFT, S-1, and Eniluracil. Capecitabine has demonstrated equivalent efficacy with 5-FU and has been approved as first line treatment. CPT-11 demonstrated non-crossover resistance with 5-FU and was proven to be effective treatment for patients who received prior 5-FU. CPT-11 in combination with 5-FU has demonstrated improved response rate and overall survival duration over 5-FU or CPT-11. Oxaliplatin plus 5-FU has offered another effective treatment option for colorectal cancer. Both 5-FU plus leucovorin in combination with CPT-11 or oxaliplatin are widely used first-line chemotherapies for advanced colorectal cancer. The combinations of capecitabine with CPT-11 or oxaliplatin are being developed. Several molecular targeting agents such as EGFR inhibitors and antiangiogenic agents have developed. Cetuximab induces a broad range of cellular responses in tumors expressing EGFR, enhancing sensitivity to radiotherapy and chemotherapeutic agents. A key angiogenic pathway in the stimulation of tumour growth is the vascular endothelial growth factor (VEGF) pathway, inhibited by the monoclonal antibody bevacizumab. Phase II first line and phase III second line studies of oxaliplatin in combination with bevacizumab are now in progress. Optimal combinations and sequences of treatment are being studied, since several effective regimens have become available. J Korean Soc Coloproctol 2004;20:118-123

키워드

원문 및 링크아웃 정보

  

등재저널 정보

KCI
KoreaMed
KAMS